Global Uterine Carcinosarcoma Market, By Treatment Type (Chemotherapy, Immunotherapy, Targeted Therapy, Hormone Therapy, Brachytherapy), Route of Administration (Oral, Intravenous, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029
Uterine Carcinosarcoma Market Analysis and Size
The global uterine carcinosarcoma market is expected to witness significant growth during the forecast period. Uterine carcinosarcoma is the fifth most fatal cancer in women. Increasing healthcare expenditure, government support for funding new drug launches and several screening and treatment methods are driving the market growth. There is also a higher risk of acquiring other types of cancer, such as prostate cancer, melanoma, and pancreatic cancer, to a lesser extent. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global uterine carcinosarcoma market in the forecast period 2022-2029. The expected CAGR of global uterine carcinosarcoma market is tend to be around 6.50% in the mentioned forecast period. The market was valued at USD 20 billion in 2021, and it would grow upto USD 33.10 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Uterine carcinoma is the most common type of cancer in females. It is a malignant tumor that mostly occurs in the uterus and can spread to other parts of the body. Per the American Cancer Society (ACS) reports, uterine carcinosarcoma accounts for 5% of the total global uterine cancer cases. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period
Uterine Carcinosarcoma Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment Type (Chemotherapy, Immunotherapy, Targeted Therapy, Hormone Therapy, Brachytherapy), Route of Administration (Intravenous, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Ireland), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (U.S.), Merck & Co., Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Hikma Pharmaceuticals PLC (U.K.), Fresenius Kabi AG (Germany), Amneal Pharmaceuticals LLC. (U.S.)
|
|
Market Opportunities
|
|
Global Uterine Carcinosarcoma Market Dynamics
Drivers
- Increase in Geriatric Population
The geriatric population is expected to increase the patient population globally, which boots the global hematuria treatment market in the forecast period. According to the WHO, the global elderly population is expected to reach around 2 billion by 2050 from 617 million in 2015 and the possibility of getting infected with ovarian cancer also rises high. This boost the market growth.
- Rising Demand for Oral Drugs
Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.
Opportunities
- Patent Expiration Encourages New Launches
Patent expiration of old companies can make better opportunities for the new market players. Adopting combination therapies is a significant factor contributing to the growth of the ovarian carcinoma treatment market. Further, R&D fundings are an add-on to the market.
- Increase in Cases of Uterine Carcinosarcoma
Rising prevalence and increase in incidence of uterine cancer across the globe is boosting the market growth during the forecast period. For instance, as per the World Cancer Research Foundation, uterine cancer is sixth-most commonly occurring cancer among women and the fifteenth-most commonly occurring cancer among all cancer cases. 3 out of 100 women are anticipated to be diagnosed with uterine carcinosarcoma as per the National Cancer Institute
- Rising Healthcare Awareness
Awareness among patients as well as healthcare providers about the incidence of uterine carcinosarcoma is on the rise. Patients and doctors are now more actively participating in learning about the therapies available for treating these severe diseases. This is one of the most important drivers in the market. This creates more opportunity in the market.
Restraints/Challenges
- Lack of Skilled Professionals
Lack of trained professionals who are unaware of the knowledge of the treatment methods for this disease could curb the growth of the global uterine carcinosarcoma market over a forecast period.
- High Cost
The huge expenditure of the treatment methods surely hamper the market growth.
This global uterine carcinosarcoma market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global uterine carcinosarcoma market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Uterine Carcinosarcoma Market Scope
The global uterine carcinosarcoma market is segmented on the basis of treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment Type
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Hormone Therapy
- Brachytherapy
Route of Administration
- Intravenous
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Uterine Carcinosarcoma Market Regional Analysis/Insights
The uterine carcinosarcoma market is analysed and market size insights and trends are provided by treatment type, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the uterine carcinosarcoma market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific is expected to have the highest market growth due to rise in the number of people suffering from endometrial cancer in densely populated countries, such as India and China, and improvement of healthcare infrastructure in the region.
North America dominates the market due to high prevalence and rise in incidence rates of endometrial cancer, increasing geriatric population.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Uterine Carcinosarcoma Market Share Analysis
The uterine carcinosarcoma market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to uterine carcinosarcoma treatment market.
Key players operating in the uterine carcinosarcoma market include:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd.(Ireland)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Eli Lilly and Company (U.S.)
- Merck & Co., Inc. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Hikma Pharmaceuticals PLC (U.K.)
- Fresenius Kabi AG (Germany)
- Amneal Pharmaceuticals LLC. (U.S.)
SKU-